{
    "nct_id": "NCT03439735",
    "official_title": "Prospective Evaluation of Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor in Hormone Receptor (HR) Positive Metastatic Breast Cancer (MBC)",
    "inclusion_criteria": "* Male or Female\n* 18 years or older\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Metastatic (stage IV) breast cancer or locally advanced breast cancer\n* Estrogen Receptor (ER) and/or Progesterone Receptor (PR) positive, HER2- negative\n* Treatment na√Øve in metastatic or locally advanced setting and planning to undergo treatment with endocrine therapy (ET) and palbociclib OR receiving first-line ET and palbociclib for metastatic or locally advanced disease.\n* Premenopausal women and men must be treated with concurrent luteinizing hormone-releasing hormone (LHRH) agonist as would be standard-of-care.\n* Evaluable or measurable disease.\n* Tissue from a metastatic site must be available within past 6 months prior to therapy initiation.\n* Ability to give voluntary informed consent\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Any pregnant or nursing woman\n* No history of another primary malignancy within past 5 years. Patients with prior history of in situ cancer or basal or localized squamous cell skin cancer are eligible.",
    "miscellaneous_criteria": ""
}